CeriBell, Inc. develops medical technology for diagnosing and monitoring serious neurological conditions in acute-care settings. Its Ceribell System is a point-of-care electroencephalography, or EEG, platform that combines portable hardware with AI-powered algorithms for rapid brain monitoring in hospitals. The system is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S.
Company updates commonly address quarterly and annual financial results, adoption of the Ceribell System, FDA clearances for the Clarity algorithm and delirium monitoring, and regulatory designations tied to additional neurological indications such as large vessel occlusion stroke. Ceribell also issues announcements on investor conference participation and other public-company communications.
Ceribell (CBLL) has commercially launched its delirium monitoring solution, expanding its point-of-care brain monitoring platform beyond seizure detection.
The launch follows a pilot across multiple hospitals already using the platform for seizure detection and FDA 510(k) clearance in December 2025. The solution uses the same hardware to analyze electrical brain activity and support delirium screening and monitoring alongside bedside clinical evaluations. CMS granted a New Technology Add-on Payment of up to $2,171 per eligible Medicare patient case using the solution, effective October 1, 2026, subject to eligibility criteria and payment rules.
Ceribell (CBLL) will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
CFO Scott Blumberg will join a fireside chat in New York City at 7:00 a.m. PST / 10:00 a.m. EST. A live and archived webcast will be available in the Investor Relations section of Ceribell's website.
Ceribell (CBLL) will release its third-quarter 2026 financial results after the close of trading on November 3, 2026.
Management will discuss the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET that day. A live and archived webcast will be available on Ceribell’s Investor Relations website.
Ceribell (CBLL) received FDA 510(k) clearance for new software that adds quantitative brain-activity trending and amplitude-integrated analysis to its monitoring system.
The clearance has no age restriction, covering premature newborns as well as adults. The software will add three capabilities: Alpha-Delta Ratio and Relative Alpha trending, which can help identify signs of brain distress and reduced blood flow; burst suppression monitoring, which can help guide sedation adjustments; and amplitude-integrated electroencephalography (EEG), a simplified view of brain electrical activity over time. The latter supports neonatal assessment and complements adult intensive-care monitoring.
Ceribell expects to integrate the features through an automatic software update in the first half of 2027.
Ceribell (Nasdaq: CBLL) reported second quarter 2026 revenue of $28.1 million, up 33% year over year, driven by new account additions and higher utilization, with 712 active accounts. Product revenue was $21.2 million and subscription revenue $6.9 million, up 33% and 30% respectively.
Gross profit reached $25.9 million, with gross margin improving to 92%, aided by manufacturing efficiencies, a Vietnam production line, and one-time tariff refunds. Operating expenses rose 37% to $45.9 million, leading to a net loss of $19.3 million ($0.51 per share). Cash, cash equivalents, and marketable securities totaled $129.3 million. Ceribell obtained multiple FDA 510(k) clearances, secured a new credit facility with access to $60 million of committed capital, received an NTAP for its delirium monitoring solution effective October 1, 2026, and raised 2026 revenue guidance to $114–117 million, implying 28–31% growth over 2025.
Ceribell (Nasdaq: CBLL) announced U.S. FDA 510(k) clearance for two new AI algorithms integrated into its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. These enhancements are part of the Ceribell point-of-care brain monitoring system used in critical-care settings.
The Artifact Reduction algorithm uses AI trained on Ceribell’s own extensive real-world artifact dataset to recognize and identify non-seizure signal disturbances from equipment, movement, and other physiological sources, simplifying EEG interpretation. The Epileptiform Abnormality Detection capability analyzes continuous EEG recordings, flags epileptiform abnormalities along the ictal-interictal continuum, and presents neurologists with an organized, high-confidence starting point, aiming to accelerate review and support timely clinical decisions.
According to Ceribell, the update builds on its POC system that can initiate bedside monitoring in as few as five minutes and is designed to deploy seamlessly with no software downtime or installation.
Ceribell (Nasdaq: CBLL) announced that the U.S. Centers for Medicare & Medicaid Services has granted a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible Medicare inpatient case for use of the Ceribell Delirium Monitor System, effective October 1, 2026.
The NTAP follows the system’s December 2025 FDA 510(k) clearance as the first and only FDA-cleared device to aid in delirium screening and monitoring. Built on Ceribell’s existing point-of-care EEG technology for detecting nonconvulsive seizures and electrographic status epilepticus, the unified platform now supports both seizure and delirium monitoring in a single bedside system for critically ill patients.
Ceribell (Nasdaq: CBLL) appointed Thomas “Tom” West and Sharon O’Keefe to its Board of Directors as the company continues expanding adoption of its point-of-care brain monitoring platform, which is now deployed in more than 680 U.S. hospitals.
West brings extensive medtech commercialization experience, having served as President and CEO of Nalu Medical, acquired by Boston Scientific for $600 million in January 2026, and of Intersect ENT, acquired by Medtronic for $1.1 billion. He also previously held senior roles at Hologic and Johnson & Johnson and serves on multiple healthcare company boards. O’Keefe offers deep health-system operating expertise, most recently as President of the University of Chicago Medical Center and COO of the University of Chicago Medicine health system, overseeing more than $2 billion in annual operating revenue, and holding prior leadership roles at several major academic medical centers.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston. The session is scheduled for Wednesday, August 12, 2026, at 6:00 a.m. PDT / 9:00 a.m. EDT, with a live and archived webcast available in the Investor Relations section of the Ceribell website.
Ceribell (Nasdaq: CBLL) will release its second quarter 2026 financial results after market close on Monday, August 10, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with live dial-in options and webcast access via the company’s investor relations website.